← back to search

Sherrie L. Perkins

University of Utah · US
Area of research
Pathology and Forensic Medicine · Public Health, Environmental and Occupational Health
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Acute Lymphoblastic Leukemia research, Viral-associated cancers and disorders, and Chronic Lymphocytic Leukemia Research.
h-index
58
citations
11,451
works
258
NIH funding
primary concept
email

Recent publications

Significant Variability in the Identification and Reporting of Band Neutrophils by Participants Enrolled in the College of American Pathologists Proficiency Testing Program: Time for a Change
Archives of Pathology & Laboratory Medicine 2023cited by 9position: middledoi
Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children’s Oncology Group AALL0434
Journal of Clinical Oncology 2020cited by 71position: middledoi
<i>IRF4</i> translocation status in pediatric follicular and diffuse large B‐cell lymphoma patients enrolled in Children's Oncology Group trials
Pediatric Blood & Cancer 2019cited by 31position: middledoi
Overall survival of children and adolescents with mature B cell non‐Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with <scp>FAB</scp>/<scp>LMB</scp> 96: A report from the <scp>FAB</scp>/<scp>LMB</scp> 96 study group
British Journal of Haematology 2018cited by 59position: middledoi
Excellent outcomes in children and adolescents with <scp>CNS</scp><sup>+</sup> Burkitt lymphoma or other mature B‐<scp>NHL</scp> using only intrathecal and systemic chemoimmunotherapy: results from <scp>FAB</scp>/<scp>LMB</scp>96 and <scp>COG ANHL</scp>01P1
British Journal of Haematology 2018cited by 28position: middledoi
Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,<i>in-vitro</i> proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model
OncoImmunology 2018cited by 22position: middledoi
Genetic evaluation of juvenile xanthogranuloma: genomic abnormalities are uncommon in solitary lesions, advanced cases may show more complexity
Modern Pathology 2017cited by 46position: middledoi
Genomic analysis of follicular dendritic cell sarcoma by molecular inversion probe array reveals tumor suppressor-driven biology
Modern Pathology 2017cited by 38position: middledoi
The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL
Oncotarget 2017cited by 34position: middledoi
Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report
British Journal of Haematology 2017cited by 18position: middledoi
Clinical utility of next‐generation sequencing in the diagnosis of hereditary haemolytic anaemias
British Journal of Haematology 2016cited by 97position: middledoi
Rare Pediatric Non-Hodgkin Lymphomas: A Report From Children's Oncology Group Study ANHL 04B1
Pediatric Blood & Cancer 2016cited by 55position: middledoi
Current status and future directions of T‐lymphoblastic lymphoma in children and adolescents
British Journal of Haematology 2016cited by 53position: lastdoi
Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy
American Journal of Clinical Pathology 2016cited by 37position: middledoi
Bone Marrow Synoptic Reporting for Hematologic Neoplasms: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center
Archives of Pathology & Laboratory Medicine 2016cited by 23position: middledoi
Revised International Pediatric Non-Hodgkin Lymphoma Staging System
Journal of Clinical Oncology 2015cited by 235position: middledoi
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow‐positive <scp>B</scp>urkitt lymphoma/leukaemia: a Children's Oncology Group Report
British Journal of Haematology 2014cited by 130position: middledoi
Advanced stage anaplastic large cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: A report from the children's oncology group
Pediatric Blood & Cancer 2014cited by 82position: middledoi
Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm
Modern Pathology 2014cited by 52position: middledoi
microRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma
Blood 2013cited by 90position: middledoi
Disseminated lymphoblastic lymphoma in children and adolescents: results of the <scp>COG A</scp>5971 trial: a report from the <scp>C</scp>hildren's <scp>O</scp>ncology <scp>G</scp>roup
British Journal of Haematology 2013cited by 85position: middledoi
Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature <scp>B</scp>‐<scp>NHL</scp>: a <scp>C</scp>hildren's <scp>O</scp>ncology <scp>G</scp>roup <scp>R</scp>eport
British Journal of Haematology 2013cited by 60position: middledoi
Rituximab pharmacokinetics in children and adolescents with <i>de novo</i> intermediate and advanced mature B‐cell lymphoma/leukaemia: a Children's Oncology Group report
British Journal of Haematology 2013cited by 39position: middledoi
The immunophenotype of <scp>T</scp> ‐lymphoblastic lymphoma in children and adolescents: a <scp>C</scp> hildren's <scp>O</scp> ncology <scp>G</scp> roup report
British Journal of Haematology 2012cited by 114position: lastdoi
Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy
Blood 2012cited by 94position: middledoi
Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling
Blood 2012cited by 79position: middledoi
Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: A report from the Children's Oncology Group
Pediatric Blood & Cancer 2012cited by 57position: middledoi
<scp>TP</scp>53 pathway analysis in paediatric <scp>B</scp>urkitt lymphoma reveals increased <i><scp>MDM</scp>4</i> expression as the only <scp>TP</scp>53 pathway abnormality detected in a subset of cases
British Journal of Haematology 2012cited by 26position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mitchell S. Cairo · New York Medical College13 papers (2012–2019)Thomas G. Gross · Phoenix Children's Hospital11 papers (2012–2020)Lauren Harrison · The Ohio State University Wexner Medical Center9 papers (2012–2018) · 8 papers (2012–2018)Lynette M. Smith · Te Pūkenga8 papers (2012–2016)Rodney R. Miles · University of Utah6 papers (2012–2020)Paul J. Galardy · Mayo Clinic in Arizona5 papers (2013–2018)Megan S. Lim · Memorial Sloan Kettering Cancer Center5 papers (2012–2020) · 5 papers (2012–2018)Amanda Termuhlen · Nationwide Children's Hospital4 papers (2012–2019)Matthew J. Barth · Roswell Park Comprehensive Cancer Center4 papers (2013–2018) · 4 papers (2012–2018)Janet Ayello · New York Medical College3 papers (2017–2018)James R. Anderson · Merck & Co., Inc., Rahway, NJ, USA (United States)3 papers (2012–2018)Mohamed E. Salama · The University of Texas at San Antonio Health Science Center3 papers (2014–2016) · 3 papers (2013–2018)Carmella van de Ven · New York Medical College3 papers (2017–2018)Ross Pinkerton · University of Leicester3 papers (2012–2018) · 3 papers (2012–2013)Anne Aupérin · Inserm3 papers (2012–2018)